Introduction
Chronic pancreatitis (CP) is a progressive and irreversible fibro-inflammatory disease of the pancreas, characterized by acinar loss and fibrosis, for which no curative therapy exists. Secreted osteopontin (sOPN) is a matricellular cytokine increasingly recognized as a key mediator of fibrosis in multiple organs, including the liver, lung and pancreas. However, its potential as a therapeutic target in CP remains unexplored.
Aims & Methods
This study investigated whether sOPN contributes to pancreatic fibrogenesis in experimental CP. CP-like injury was induced in mice by six intraperitoneal cerulein injections (50 µg/kg every hour) three days per week, combined with ethanol injections (33%, 3×/week) for 6 weeks. Anti-OPN antibody (200µg, 3×/week) was administered to neutralize secreted OPN. Serum sOPN levels were measured by ELISA. Pancreatic RNA was isolated for qPCR analysis of inflammatory and fibrotic markers, and fibrosis was additionally evaluated histologically using Sirius Red staining. Immunohistochemistry for α-SMA was performed and quantified to evaluate pancreatic stellate cell activation.
Results
Six-weekly injections of cerulein and ethanol induced a consistent CP-like phenotype, characterised by acinar cell loss, inflammatory cell infiltration and fibrosis. Circulating sOPN levels were significantly higher in mice with CP compared to healthy mice, and significantly decreased upon anti-OPN-Ab treatment (Δ = -98514; 95% CI -180392 to -16636; p = 0.0209). Histological analysis showed a significant reduction in pancreatic fibrosis, with less collagen deposition on Sirius Red staining (Δ = -1.648, 95% CI -2.766 to -0.530; p = 0.0064). Immunohistochemical analysis of α-SMA also showed a significant reduction, suggesting decreased pancreatic stellate cell activation (Δ = -3.636; 95% CI -5.351 to -1.920; p = 0.0004). Pancreatic α-SMA and CTGF mRNA expression showed a significant reduction after OPN blockade (α-SMA: Δ = -72.91; 95% CI -117.8 to -28.04; p = 0.0028; CTGF: Δ = -3.112; 95% CI -5.542 to -0.681; p = 0.0147), accompanied by significant downregulation of pro-fibrotic genes, including Col1a1 (Δ = -6.467; 95% CI -11.02 to -1.911; p = 0.0077), Col3a1 (Δ = -5.097; 95% CI -8.201 to -1.994; p = 0.0026), and MMP2 (Δ = -2.659; 95% CI -5.318 to -0.0002; p = 0.0500), indicating attenuation of the fibrotic phenotype.
Conclusion
Blocking secreted OPN significantly reduced serum OPN levels, markers of pancreatic stellate cell activation, and markers of fibrogenic gene expression in experimental CP. Additionally, histology showed significantly less collagen deposition, identifying secreted OPN as a potential therapeutic target in CP.